B. Braun’s DoseTrac Software First to Provide Inbound Admission Discharge and Transfer Capability

In an industry first that will help healthcare providers improve patient safety and reduce medication errors as they streamline care, B. Braun Medical has announced the launch of its DoseTrac Infusion Management Software with Inbound Admission, Discharge and Transfer (ADT) Interface Capabilities.

Advertisement

A leader in infusion therapy, B. Braun was the first infusion pump vendor to offer real-time wireless information when it introduced its DoseTrac Infusion Management Software. The ADT Interface capability, also an industry-first, makes connectivity easier and less expensive, says the company. It’s one of a series of connectivity programs the company expects to introduce for DoseTrac to support better communication among clinical, administrative and ancillary applications.

The ADT Interface allows room and bed information to be posted to real-time views and specified reports within DoseTracTM. Providing more specific information, the ADT Interface allows clinicians to be more effective and time efficient, says B. Braun. For example, clinicians with access to the ADT information spend less time finding pumps that are reporting alerts or alarms and more time caring for patients: When an alarm sounds on an infusion pump, DoseTrac with ADT will highlight the alarm for clinicians and provide them with detailed information – including bed number – so they can quickly identify the alarm’s location, as well as why it’s sounding.

DoseTrac™ with ADT Interface receives real-time notification of patient arrivals, movements and departures, to help improve the efficiency of the services provided by clinicians. In-depth patient information and locations are received and posted in real-time to specific views and reports within DoseTracTM to help healthcare professionals better interpret and make use of infusion information.

Learn more about DoseTrac here. Learn more about B. Braun.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.